This press release contains forward-looking statements including statements related to UNITY's understanding of cellular senescence and the role it plays in diseases of aging, the potential for UNITY ...

Anirvan Ghosh is the CEO of Unity Biotechnology Inc. He has a distinguished career in the biotechnology industry, with a strong focus on developing innovative therapies for age-related diseases. Ghosh ...

SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UBX) (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases ...

UNITY Biotechnology, Inc. has announced that it will present data from its ASPIRE Phase 2B study on its senolytic candidate, UBX1325, targeting diabetic macular edema at the upcoming ARVO 2025 Annual ...

UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced complete 36-week results from the Phase ...

Fintel reports that on August 22, 2024, Rodman & Renshaw initiated coverage of Unity Biotechnology (NasdaqGS:UBX) with a Buy recommendation. As of August 6, 2024, the average one-year price target for ...

Unity Biotechnology's workforce shake-up goes all the way to its C-suite executives, while Mammoth Biosciences is laying off 24 staffers. (Andrii Yalanskyi/iStock/Getty Images Plus) Unity ...

I believe that a good speculative biotech to go over for the "Exclusive BAC Subscribers Article" would be Unity Biotechnology (UBX). The reason why I believe that this is another good biotech to go ...

UNITY Biotechnology, Inc. (“UNITY” or the “Company”) [Nasdaq: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced the entry into a ...

The primary endpoint miss was driven fully by the 20-week data, which was the only measure out of 10 in which UBX1325 was inferior to aflibercept. (iStock / Getty Images Plus) Unity Biotechnology’s ...